← All trials
NCT07305207
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2026
- Primary completion
- Jun 1, 2027
- Completion date
- Jan 31, 2028
- First posted
- Dec 26, 2025
- Last posted
- Dec 26, 2025
- Enrollment
- 32
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Dalhousie UniversityLead sponsor
- Canadian Center for VaccinologyCollaborator
- McGill UniversityCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.